[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200970731A1 - Рекомбинантные антигены цитомегаловируса человека (hcmv) - Google Patents

Рекомбинантные антигены цитомегаловируса человека (hcmv)

Info

Publication number
EA200970731A1
EA200970731A1 EA200970731A EA200970731A EA200970731A1 EA 200970731 A1 EA200970731 A1 EA 200970731A1 EA 200970731 A EA200970731 A EA 200970731A EA 200970731 A EA200970731 A EA 200970731A EA 200970731 A1 EA200970731 A1 EA 200970731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hcmv
human cytomegalovirus
recombinant antigens
cytomegalovirus recombinant
antigenic regions
Prior art date
Application number
EA200970731A
Other languages
English (en)
Inventor
Никола Гаргано
Элиза Бегетто
Андреа Спадони
Франческa Де Паолис
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA200970731A1 publication Critical patent/EA200970731A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Описанное здесь изобретение относится к способу идентификации антигенных участков белков HCMV, вовлеченных в иммунный ответ В-клеток человека на HCMV-инфекцию, способу объединения таких антигенных участков в форму химерных слитых продуктов и их применению в качестве диагностических и иммуногенных агентов.
EA200970731A 2007-02-07 2008-02-05 Рекомбинантные антигены цитомегаловируса человека (hcmv) EA200970731A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101864 2007-02-07
PCT/EP2008/000876 WO2008095677A1 (en) 2007-02-07 2008-02-05 Recombinant antigens of human cytomegalovirus (hcmv)

Publications (1)

Publication Number Publication Date
EA200970731A1 true EA200970731A1 (ru) 2010-02-26

Family

ID=38229391

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970731A EA200970731A1 (ru) 2007-02-07 2008-02-05 Рекомбинантные антигены цитомегаловируса человека (hcmv)

Country Status (13)

Country Link
US (1) US20100068229A1 (ru)
EP (1) EP2114991A1 (ru)
JP (1) JP2010517544A (ru)
KR (1) KR20090126256A (ru)
CN (1) CN101605808A (ru)
AU (1) AU2008213356A1 (ru)
BR (1) BRPI0807095A2 (ru)
CA (1) CA2677455A1 (ru)
EA (1) EA200970731A1 (ru)
IL (1) IL200187A0 (ru)
MX (1) MX2009008248A (ru)
SG (1) SG178761A1 (ru)
WO (1) WO2008095677A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
JP5712513B2 (ja) * 2010-07-07 2015-05-07 富士レビオ株式会社 ヒトサイトメガロウイルス感染の検出方法
WO2012099884A1 (en) * 2011-01-18 2012-07-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for amplification and detection of prions
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2019020480A1 (en) * 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60184A (en) * 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
KR100287083B1 (ko) * 1992-05-23 2001-04-16 장 스테판느 B형 간염 표면 항원 및 다른 항원을 포함하는 조합 백신
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
WO1998002746A1 (en) * 1996-07-12 1998-01-22 Akzo Nobel N.V. Peptide reagent for the detection of human cytomegalovirus (cmv)
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
WO2003010198A1 (en) 2001-07-26 2003-02-06 Kenton Srl Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques

Also Published As

Publication number Publication date
US20100068229A1 (en) 2010-03-18
MX2009008248A (es) 2009-08-12
IL200187A0 (en) 2010-04-15
CN101605808A (zh) 2009-12-16
AU2008213356A1 (en) 2008-08-14
SG178761A1 (en) 2012-03-29
KR20090126256A (ko) 2009-12-08
CA2677455A1 (en) 2008-08-14
WO2008095677A1 (en) 2008-08-14
JP2010517544A (ja) 2010-05-27
EP2114991A1 (en) 2009-11-11
BRPI0807095A2 (pt) 2014-04-22

Similar Documents

Publication Publication Date Title
EA200970731A1 (ru) Рекомбинантные антигены цитомегаловируса человека (hcmv)
BRPI0608342A2 (pt) antìgenos recombinantes quiméricos de toxoplasma gondii
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
GB2513768A (en) Complexes of cytomegalovirus proteins
WO2012034025A3 (en) Human cytomegalovirus vaccine
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
MY156286A (en) Human il-23 antigen binding proteins
PE20141435A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA200900795A1 (ru) Вакцина
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2012046061A3 (en) Clostridium difficile antigens
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
AR061894A1 (es) Vacunas para malaria
EA201391011A1 (ru) Мономерные и мультимерные иммуногенные пептиды
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2012061910A3 (pt) Principais domínios e epítopos imunoprotetores da nucleosideo hidrolase de leishmania (l) donovani para uso em vacinação, imunoterapia e diagnóstico
WO2006037383A8 (en) Piscirickettsia salmonis antigens and use thereof
Tabuchi et al. Identification of the immunogenic outer membrane proteins of relapsing fever Borrelia